Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1

Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1

The purpose of this study is to evaluate the safety and tolerability of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.

Study Overview

• Status: Unknown
• Conditions: HIV
• Intervention / Treatment: Biological: VAC-3S

• Study Type: Interventional
• Enrollment (Anticipated): 15
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• France
  • Paris, France, 75013
    • Hopital Pitie Salpetriere
  • Paris, France, 75014
    • Hôpital Cochin Saint Vincent de Paul

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• HIV-1 infected patient,
• Age between 18 and 60 years,
• ART (Anti Retroviral Therapy) initiation ≥ 1 year ago,
• Plasma HIV RNA ≤ 200 copies/ml in the past 12 months,
• Plasma HIV RNA ≤ 50 copies/ml at the screening visit,
• CD4+ T cell count ≥ 200 cells/mm3,
• Nadir CD4+ T cell count ≥ 100 cells/mm3,
• Contraception in women with child-bearing potential,
• A total anti-3S titer ≥ 20 A.U. at any time point of IVVAC-3S/P1 clinical trial,
• Per protocol subject having completed the IVVAC-3S/P1 study.
• Patient affiliated to a social security system,
• Patient who has understood the protocol design and provided a signed written informed consent form,
• Patient who is willing and capable of cooperating to the extent and degree required by the protocol,
• Patient whom the investigator believes he/she can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) and he/she will be available for all scheduled visits at the investigational site.

Exclusion Criteria:

• Administration of VAC-3S in the past year,
• Chronic active liver disease,
• History of HCV co-infection or ongoing replicating HCV (positive RT-PCR) or HBV (positive HbS Ag) coinfection,
• Any immunotherapy (e.g. IL-2, IL-7, growth hormone…) in the past year at the exception of VAC-3S,
• Any immunosuppressive therapy (glucocorticoids, cyclosporine, methotrexate) or chronic non-steroidal anti-inflammatory treatment in the past month,
• Ongoing pregnancy,
• Breastfeeding women,
• Patient with known sensitivities to investigational drug (see please the CIB),
• History of allergy to any vaccine,
• Any severe chronic condition that would interfere with the study,
• History of auto-immune disease,
• Organ transplant,
• Splenectomy,
• Psychiatric disorder significant enough to hinder participation as assessed by the investigator,
• Patient who has participated in a clinical research trial in the 30 days preceding the screening visit (V-1M-1).
• Patients with contraindications to intramuscular injections including, but not limited to, patients with thrombocytopenia and/or anomalies of the coagulation system,
• Any uncontrolled chronic or acute condition that in the opinion of the investigator would compromise the safety of the patient or the ability to properly administer the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VAC-3S; 32µg/ml corresponding to 16µg/vaccination	Biological: VAC-3S; Administered via intra-muscular injection in the arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients who tolerated 3 vaccinations with VAC-3S 16µg/mL at 4-weeks interval determined by safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.	From Day 0 to week 16

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of patients who tolerated a fourth booster injection of VAC-3S 16µg/mL determined by safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.	From Week 16 to Week 48
Anti-3S antibody titers	From Day 0 to Week 48
Markers of progression to AIDS. Markers include CD4+ cell count, viral load, and phenotypic markers of lymphocyte differentiation and activation	From Day 0 to Week 48

Collaborators and Investigators

• Sponsor: InnaVirVax

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Anticipated): April 1, 2017
• Study Completion (Anticipated): April 1, 2017

Study Registration Dates

• First Submitted: January 30, 2015
• First Submitted That Met QC Criteria: March 10, 2015
• First Posted (Estimate): March 17, 2015

Study Record Updates

• Last Update Posted (Estimate): June 17, 2016
• Last Update Submitted That Met QC Criteria: June 16, 2016
• Last Verified: October 1, 2015

More Information

Terms related to this study

• Other Study ID Numbers: IVVAC-3S/P2